Janssen sues Mylan to block generic of schizophrenia drug
A Johnson & Johnson company, Janssen Pharmaceuticals, is seeking a court order blocking Mylan from making copies of its schizophrenia treatment, Invega Trinza, until its patent expires in 2036.
Appeals court sides with Pfizer, Merck KGaA in $5bn suit
The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
MSD petitions SCOTUS over $2.5bn patent verdict
MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
PTAB cancels Imbruvica patent claims in blow for AbbVie
The US Patent Trial and Appeal Board has invalidated parts of an AbbVie patent covering blood disease drug Imbruvica.
Genmab locked in J&J royalty payments dispute
Danish biotech Genmab has commenced binding arbitration of two matters with Janssen Biotech, a Johnson & Johnson company, over royalty payments for a cancer drug.
ERS Genomics appoints vice-president of IP
ERS Genomics, the company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, has appointed Michael Arciero as vice-president of IP and commercial development.
Bausch Health settles with Sun Pharma
Canada-based Bausch Health has dropped its litigation against Indian generic maker Sun Pharma as part of a settlement agreement.
Illumina to acquire Jeff Bezos-backed cancer testing company
Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.
BMS and Dr Reddy’s settle Revlimid suit with generics licence
Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.
Gilead accused of illegally paying to delay HIV drug competition
Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
